Figure 1.
Figure 1. Distribution of myeloid neoplasms in patients with concomitant non-LCH and genetic analysis of both disorders. (A) Pie chart demonstrating proportion of non-LCH patients with concomitant myeloid neoplasm and types of myeloid neoplasms diagnosed. ET, essential thrombocytosis; MDS, myelodysplastic syndrome; MF, primary myelofibrosis; PV, polycythemia vera; sAML, secondary acute myeloid leukemia transformed from antecedent hematological malignancy. (B) Genetic analysis of non-LCH and concomitant myeloid neoplasm. Each patient is noted by a column. Patients had clinical diagnosis of ECD or an overlap of ECD plus LCH or ECD/LCH plus Rosai Dorfman disease (RDD) based on tissue biopsy and clinical evaluation in addition to a form of WHO-classified myeloid. Mutations identified in histiocytosis tissue lesion biopsy alone in each patient are noted in the middle boxes, and those mutations detected in PB or BM mononuclear cells are noted in bottom boxes.

Distribution of myeloid neoplasms in patients with concomitant non-LCH and genetic analysis of both disorders. (A) Pie chart demonstrating proportion of non-LCH patients with concomitant myeloid neoplasm and types of myeloid neoplasms diagnosed. ET, essential thrombocytosis; MDS, myelodysplastic syndrome; MF, primary myelofibrosis; PV, polycythemia vera; sAML, secondary acute myeloid leukemia transformed from antecedent hematological malignancy. (B) Genetic analysis of non-LCH and concomitant myeloid neoplasm. Each patient is noted by a column. Patients had clinical diagnosis of ECD or an overlap of ECD plus LCH or ECD/LCH plus Rosai Dorfman disease (RDD) based on tissue biopsy and clinical evaluation in addition to a form of WHO-classified myeloid. Mutations identified in histiocytosis tissue lesion biopsy alone in each patient are noted in the middle boxes, and those mutations detected in PB or BM mononuclear cells are noted in bottom boxes.

Close Modal

or Create an Account

Close Modal
Close Modal